Acute Monoblastic/monocytic Leukemia
Watchlist
Retrieved
2021-01-23
Source
Trials
—
Genes
CEBPA,
KMT2A,
DNMT3A,
FANCB,
FANCA,
FANCM,
SBDS,
SLX4,
BRCA1,
FANCG,
FANCF,
FANCE,
CTC1,
FANCD2,
FANCC,
RAD51C,
RAD51,
ERCC4,
UBE2T,
BRIP1,
BLM,
XRCC2,
PALB2,
FANCI,
FANCL,
MAD2L2,
RUNX1,
ELANE,
BCL2,
RUNX1T1
CEBPA,
KMT2A,
DNMT3A,
FANCB,
FANCA,
FANCM,
SBDS,
SLX4,
BRCA1,
FANCG,
FANCF,
FANCE,
CTC1,
FANCD2,
FANCC,
RAD51C,
RAD51,
ERCC4,
UBE2T,
BRIP1,
BLM,
XRCC2,
PALB2,
FANCI,
FANCL,
MAD2L2,
RUNX1,
ELANE,
BCL2,
RUNX1T1,
ABCB1,
IDH1,
KIT,
CD34,
MECOM,
NUP98,
IDH2,
TBC1D9,
FLT3,
TP53,
NCAM1,
CCR7,
NPM1,
TSC2,
SCT,
CSF3,
CD33,
KAT6A,
ASXL1,
CXCR4,
MYH11,
JAK2,
MDM2,
CSF3R,
PIK3CD,
CPOX,
MPO,
EBP,
ABCC1,
TET2,
TBX22,
MCL1,
EZH2,
BCR,
WT1,
VEGFA,
VDR,
CTNNB1,
HOXA9,
PIK3CA,
MIR155,
PIK3CB,
MDM4,
PIK3CG,
ABCG2,
CDKN2B,
CD38,
TSC1,
MLLT3,
GATA2,
BAALC,
IL2,
NRAS,
IL6,
NSD1,
MSH3,
PTP4A3,
HIF1A,
CDKN2A,
CD19,
CSF2,
CALR,
PTPN11,
CREBBP,
FAS,
ABCC3,
KRAS,
RARA,
ABL1,
ACTB,
ISG20,
CBFB,
AKT1,
SPP1,
IL18,
BAX,
CXCL8,
MLLT10,
LGALS3,
GFI1,
MLANA,
FLT1,
TESC,
MTOR,
GABPA,
IL2RA,
IL3RA,
HAVCR2,
MAPK8,
CDKN1B,
PML,
PTPA,
CDK9,
SEPTIN6,
MIR34A,
DCK,
MAP2K7,
NFE2L2,
VEGFC,
AURKA,
SMR3B,
SUB1,
KDM1A,
NFATC1,
NXT1,
VIM,
PPARG,
IL1RAP,
NME1,
ELL,
HMGA2,
DEK,
NOTCH1,
ASXL2,
NR4A3,
ARID1B,
STAT3,
CD200,
TXNIP,
MVP,
LRP1,
EFS,
TRIB2,
KDR,
FOXP3,
HPGDS,
RET,
BCL2L11,
EIF2AK2,
BCLAF1,
ADGRG1,
SRSF2,
SLC12A3,
MRPL28,
BABAM2,
SOAT1,
MEIS1,
INPP5D,
SIRT6,
LMO2,
NT5E,
H3P10,
NUP214,
CD6,
FGFR1,
ALL1,
CD44,
MIR335,
FABP4,
ETS1,
CD80,
ERG,
DAPK1,
CAB39L,
ERCC2,
SLCO6A1,
CBL,
LIN28B,
ATM,
DNMT1,
MALAT1,
GSTK1,
CDA,
MIR142,
CSF1R,
ANPEP,
ABO,
H3P9,
CHEK1,
GSTT1,
MIR29B2,
MARCKSL1,
MIR29B1,
AHR,
GATA1,
WLS,
XIAP,
CTDSPL,
CIB1,
MTSS1,
MIR451A,
HDAC4,
ATG7,
MIR223,
HDAC9,
MIR483,
IKBKE,
NCOR1,
LEF1-AS1,
MIR217,
LILRB2,
IKZF1,
NR1I3,
ABI1,
CD96,
NCOA2,
MIR17HG,
TANK,
BCL2L10,
MIR29A,
MIR363,
SEMA3A,
ABCB6,
H4C15,
LRPPRC,
TRIM13,
MIR342,
GPHN,
APOBEC3B,
CARTPT,
CDKN2B-AS1,
LOC646762,
H4C5,
H4C8,
H4C3,
SYCE1L,
H4C11,
H4C12,
MIR181A1HG,
H4C6,
H4C4,
H4C1,
GFI1B,
H4C9,
HOTTIP,
MIR3151,
KLRC4-KLRK1,
MLRL,
APOBEC3A_B,
CDR3,
CSAG2,
PERCC1,
RN7SL263P,
PTP4A2,
H4C2,
H4C13,
CXADRP1,
H4C14,
NCF1,
NCR1,
NCR2,
MIR663A,
KLF4,
POTEF,
MIR210,
AURKB,
USP2,
VTRNA2-1,
ASH2L,
SOCS3,
MBD4,
DDX18,
SOCS2,
INPP4B,
DLK1,
BMI1P1,
PIR,
GAS7,
CNTNAP1,
MIR212,
KLHL1,
MIR21,
ZBTB7A,
HERC5,
GLIS2,
ADIPOR1,
FIS1,
DERL3,
TWIST2,
TMEM132D,
SYCP3,
H4-16,
EHD3,
ERVW-1,
CD274,
TBK1,
OSCP1,
CCDC26,
SIRPA,
IL23R,
CLEC12A,
ZNF296,
APOBEC3A,
CTAG1A,
SYVN1,
MAML2,
CHORDC1,
WT1-AS,
BIRC6,
TIGAR,
SLC12A9,
RPRM,
PBK,
PRDM16,
ZC3H15,
SOX6,
VSIR,
GORASP1,
RMDN3,
WNK1,
PHF23,
TUG1,
ASRGL1,
ULBP1,
PARP9,
UGT1A1,
BCL11A,
CMPK1,
PHF6,
EBF3,
LATS2,
MIR203A,
MIR126,
MIR130A,
CHEK2,
MIR132,
MIR143,
MIR144,
MIR145,
MIR146A,
KAT7,
FGFR1OP,
GLIPR1,
MIR149,
MIR150,
LILRB4,
MIR183,
BCORL1,
SLC27A5,
MLLT11,
MIR192,
SEPTIN9,
KDM5B,
NES,
AKAP13,
ACOT7,
GNL3,
MIR122,
TUSC7,
SAMHD1,
FRYL,
PRKD2,
CADM1,
DAPK2,
PIGN,
PRAME,
SF3B1,
RTL1,
SIRT3,
DICER1,
CSAG3,
KDM6B,
SIPA1L3,
ARHGAP26,
CASC15,
MIRLET7B,
DKK1,
KLRK1,
ZHX2,
MIR191,
AADAC,
TFPI2,
ATN1,
FOSB,
FLNA,
FOXO3,
VEGFD,
FGFR3,
FDXR,
FCGRT,
FCGR3B,
FCGR3A,
FCGR1A,
PTK2B,
F2,
EVPL,
ETV6,
ETS2,
ESR1,
EPHB4,
EPHB2,
EPHA1,
EPAS1,
EP300,
ELN,
EIF4B,
EGFR,
EGF,
E2F3,
E2F1,
GAS6,
KAT2A,
GEM,
NR4A1,
IL7R,
IL7,
IL6ST,
IL3,
IL2RG,
IGFBP2,
IFNG,
IDUA,
HTC2,
HOXC5,
HOXB2,
HOXA4,
HMOX1,
GLI1,
HMMR,
HLF,
HLA-DRB4,
HLA-A,
HIP1,
H2AX,
MSH6,
GSTM1,
GRN,
GNA12,
GLUL,
GLI3,
DUSP7,
ARID3A,
ZMYM2,
DRD2,
CD47,
CD40LG,
CD40,
CD36,
CD14,
CBFA2T3,
CASR,
CASP9,
CASP1,
BST1,
BRAF,
OPN1SW,
BCAT1,
ATR,
ASAH1,
ARR3,
AR,
APOE,
APOA1,
BIRC5,
AMFR,
AKR1B1,
JAG1,
AGER,
TLE5,
ADM,
ACR,
CD74,
CDH2,
CDK2,
CTSK,
DGUOK,
TIMM8A,
DECR1,
ACE,
DBH,
DAP,
CYP7A1,
CYP3A4,
CYP2D6,
CYP2C19,
CXADR,
CTSL,
CTSB,
CDK7,
CCN2,
CTAG1B,
CSNK1A1,
ABCC2,
CIRBP,
CHD4,
CEL,
CEBPB,
CDKN3,
CDKN1C,
CDKN1A,
CDK8,
CXCR2,
TNFRSF9,
IL17A,
IDO1,
SPN,
SPG7,
SPARC,
SOS1,
SMARCB1,
PMEL,
FBXW4,
CX3CL1,
CCL2,
SATB1,
S100A8,
RRM1,
RREB1,
RPS6KA1,
RORA,
ROBO2,
RNF2,
RING1,
RGS2,
KDM5A,
RAF1,
MOK,
NECTIN2,
PVR,
PTPRA,
PTBP1,
PSMB9,
SSX2,
STAT5A,
STAT5B,
TLR2,
YWHAE,
XPO1,
XBP1,
VCAM1,
UBE2I,
TYR,
TXN,
TTC4,
TRAF2,
NR2C2,
TOP1,
TLR4,
TLE4,
SYK,
TLE1,
TIAM1,
THPO,
TFRC,
TFE3,
TERT,
PRDX2,
TRBV20OR9-2,
TBCE,
TAZ,
MAP3K7,
SYT1,
PSMA7,
MAPK7,
MAPK1,
SMAD5,
MT1E,
MSH2,
MSD,
MMP9,
MMP2,
MLLT6,
AFDN,
MLLT1,
MITF,
CXCL9,
MAP3K5,
MATK,
SMAD4,
MYO1F,
LLGL1,
LCP2,
LCK,
RPSA,
LAMP2,
KIR3DL1,
JARID2,
JAK1,
ITGB2,
ITGAM,
IRF7,
IRF3,
MTHFR,
MYB,
PRKAR1A,
PIM1,
PRKAB1,
PRKAA2,
PRKAA1,
PPP2R2A,
POU4F1,
PMAIP1,
PLS3,
PLG,
PLCG1,
PLA2G4A,
PKD1,
PIN1,
PAX5,
MYC,
PAFAH1B1,
PA2G4,
ORC5,
NONO,
NM,
NFE2,
NF1,
NEDD8,
SEPTIN2,
NCL,
MYH9,
MYH8,
RELA
Drugs
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol,
(S)-5-(1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethylamino-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile,
1,2-bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl) amino)methyl)tetrahydrofuran-3,4-diol,
(S)-5-(1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethylamino-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile,
1,2-bis(methylsulphonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine,
1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea,
1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea,
1-[2-(Benzo[1,2,5]thiadiazol-5-ylamino)-6-(2,6-dichloro-phenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3- tert-butyl-urea,
2-((3-((4-((3-aminopropyl)amino)butyl)amino)propyl)amino)-N-((5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl)acetamide, tetrahydrochloride,
2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate,
2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}- 1H-pyrazol-3-yl)amino]- quinazolin-7-yl}oxy)propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate,
2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one,
225Ac-lintuzumab,
26 base single stranded phosphodiester DNA oligonucleotide,
5'-O-(trans-9"-octadecenoyl)-1-ß-D-arabinofuranosyl cytosine,
6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate,
Allogeneic T cells encoding an exogenous TK gene,
Allogeneic bone marrow stem cells treated ex vivo with 16,16-dimethyl prostaglandin E2,
Allogeneic ex vivo expanded umbilical cord blood cells,
Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells,
Allogeneic human dendritic cells derived from a CD34+ progenitor cell line,
Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus,
Allogeneic umbilical cord blood cells treated ex vivo with 16,16-dimethyl prostaglandin E2,
Allogeneic, umbilical cord blood-derived, ex vivo-expanded, haematopoietic CD133+ cells / allogeneic, umbilical cord blood-derived, non-expanded, haematopoietic CD133- cells,
Alvocidib,
Amonafide L-malate,
Antisense oligonucleotide 5'-d[P-Thio} (CCCTG CTCCC CCCTG GCTCC)-3',
Arsenic trioxide
(
Arsenic Trioxide Accord,
Arsenic trioxide Mylan,
Arsenic trioxide medac,
TRISENOX
),
Azacitidine
(
AZACITIDINE ACCORD,
AZACITIDINE BETAPHARM,
AZACITIDINE CELGENE,
AZACITIDINE MYLAN,
VIDAZA
),
Bisantrene hydrochloride,
Clofarabine
(
CLOLAR,
EVOLTRA,
IVOZALL
),
Combretastatin A1 diphosphate-,
Crenolanib besylate,
Daunorubicin (liposomal),
Decitabine
(
DACOGEN
),
Devimistat,
Donor lymphocyte preparation depleted of functional alloreactive T-cells,
Enasidenib
(
IDHIFA
),
Entospletinib,
Eryaspase
(
GRASPA
),
Fully human IgG1 antibody specific for CD33,
Gemtuzumab Ozogamicin
(
MYLOTARG
),
Gilteritinib
(
XOSPATA
),
Glasdegib
(
DAURISMO
),
Guadecitabine,
Histamine dihydrochloride
(
CEPLENE
),
Homoharringtonine
(
CEFLATONIN
),
Human monoclonal antibody against inhibitory killer cell lg-like receptors (1-7 F9),
Idasanutlin,
Inecalcitol,
Isocitrate dehydrogenase 2-mutant inhibitor,
Ivosidenib
(
TIBSOVO
),
L-Asparaginase
(
KIDROLASE,
SPECTRILA
),
Laromustine
(
CLORETATZNE
),
Lestaurtinib,
Lintuzumab,
Liposomal combination of cytarabine and daunorubicin
(
VYXEOS
),
Liposomal daunorubicin,
Midostaurin
(
RYDAPT
),
Mitoxantrone
(
NOVANTRONE
),
N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide,
N-(5-tert-Butylisoxazol-3-yl)-N'-{4-[7-(2-(morpholin-4-yl)ethoxy)imidazo[2,1- b][1,3]benzothiazol-2-yl]phenyl}urea di-hydrochloride salt,
N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]isonicotinamide hydrochloride,
NEDD8-activating enzyme (NAE) inhibitor,
Onvansertib,
P-ethoxy growth factor receptor-bound protein 2 (Grb2) antisense oligonucleotide,
Plerixafor
(
MOZOBIL
),
Pracinostat,
Recombinant human histone H1.3 and recombinant human N-bis-met-histone H1.3,
Recombinant human interleukin-3 truncated diphtheria toxin fusion protein
(
ELZONRIS
),
Ribonucleotide reductase R2 specific phosphorothioate oligonucleotide,
Sapacitabine,
Selinexor
(
XPOVIO
),
Tamibarotene,
Tipifarnib
(
ZARNESTRA
),
Tosedostat,
Troxacitabine,
Ulocuplumab,
Vadastuximab talirine,
Val-Leu-Gln-Glu-Leu-Asn-Val-Thr-Val (Pr1 nanopeptide, sequence 169-177, of proteinase 3),
Venetoclax
(
VENCLEXTA,
VENCLYXTO
),
Volasertib,
Vosaroxin,
Wilms' tumour 1 (WT1) vaccine,
Zosuquidar trihydrochloride,
cenisertib,
cusatuzumab,
haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate,
humanised monoclonal antibody of the IgG4 kappa isotype targeting CD47,
lysine-specific histone demethylase (LSD1, also known as KDM1A) inhibitor
Registered!
Acute monoblastic leukemia (AML-M5), is one of the most common subtypes of acute myeloid leukemia (AML; see this term) that is either comprised of more than 80% of monoblasts (AML-M5a) or 30-80% monoblasts with (pro)monocytic differentiation (AML-M5b). AML-M5 presents with asthenia, pallor, fever, and dizziness. Specific features of AML-M5 include hyperleukocytosis, propensity for extramedullary infiltrates, coagulation abnormalities including disseminated intravascular coagulation and neurological disorders. Leukemia cutis and gingival infiltration can also be seen. A characteristic translocation observed in AML-M5 is t(9;11).